| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Y Lu | |
| R W Asinger | |||
| R Branstad | |||
| R M Karim | |||
| P2860 | cites work | Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation | Q22305336 |
| Dabigatran, bleeding, and the regulators | Q28244581 | ||
| Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects | Q28247385 | ||
| Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials | Q28257083 | ||
| Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity | Q28278166 | ||
| Validation of Clinical Classification Schemes for Predicting Stroke | Q29028208 | ||
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Apixaban versus warfarin in patients with atrial fibrillation | Q29617563 | ||
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The fiamingham Study | Q34054106 | ||
| Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly | Q34152050 | ||
| Apixaban in patients with atrial fibrillation | Q34163710 | ||
| Apixaban with antiplatelet therapy after acute coronary syndrome | Q34202772 | ||
| Rivaroxaban in patients with a recent acute coronary syndrome | Q34231902 | ||
| New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper | Q34267825 | ||
| Dabigatran and postmarketing reports of bleeding | Q34332588 | ||
| Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor | Q34381344 | ||
| Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study | Q34540479 | ||
| Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects | Q34605304 | ||
| European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation | Q34651051 | ||
| Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation | Q35003773 | ||
| Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752573 | ||
| Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor | Q37841256 | ||
| The coagulopathy of chronic liver disease | Q37900633 | ||
| Stroke prevention in atrial fibrillation patients with chronic kidney disease | Q38116162 | ||
| Laboratory assessment of rivaroxaban: a review | Q38119016 | ||
| Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial | Q38459005 | ||
| Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial | Q38490930 | ||
| Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment | Q42618094 | ||
| In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | Q43235385 | ||
| The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans | Q46897672 | ||
| Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. | Q50513310 | ||
| Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. | Q51175352 | ||
| Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. | Q51328729 | ||
| Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation | Q57385465 | ||
| P433 | issue | 6 | |
| P921 | main subject | (RS)-warfarin | Q407431 |
| atrial fibrillation | Q815819 | ||
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 628-636 | |
| P577 | publication date | 2014-09-24 | |
| P1433 | published in | Journal of Clinical Pharmacy and Therapeutics | Q15753553 |
| P1476 | title | Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation | |
| P478 | volume | 39 |
| Q49713074 | Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy: A case report. |
| Q38494667 | Dose tailoring of dabigatran etexilate: obvious or excessive? |
| Q87357276 | Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation |
| Q30400249 | Reversing the anticoagulation effects of dabigatran |
| Q38728028 | Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices? |
Search more.